Mackey Sean, Aghaeepour Nima, Gaudilliere Brice, Kao Ming-Chih, Kaptan Merve, Lannon Edward, Pfyffer Dario, Weber Kenneth
Division of Pain Medicine, Stanford University School of Medicine, Stanford, California, USA
Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, California, USA.
Reg Anesth Pain Med. 2025 Feb 5;50(2):110-120. doi: 10.1136/rapm-2024-106030.
Pain affects millions worldwide, posing significant challenges in diagnosis and treatment. Despite advances in understanding pain mechanisms, there remains a critical need for validated biomarkers to enhance diagnosis, prognostication, and personalized therapy. This review synthesizes recent advancements in identifying and validating acute and chronic pain biomarkers, including imaging, molecular, sensory, and neurophysiological approaches. We emphasize the emergence of composite, multimodal strategies that integrate psychosocial factors to improve the precision and applicability of biomarkers in chronic pain management. Neuroimaging techniques like MRI and positron emission tomography provide insights into structural and functional abnormalities related to pain, while electrophysiological methods like electroencepholography and magnetoencepholography assess dysfunctional processing in the pain neuroaxis. Molecular biomarkers, including cytokines, proteomics, and metabolites, offer diagnostic and prognostic potential, though extensive validation is needed. Integrating these biomarkers with psychosocial factors into clinical practice can revolutionize pain management by enabling personalized treatment strategies, improving patient outcomes, and potentially reducing healthcare costs. Future directions include the development of composite biomarker signatures, advances in artificial intelligence, and biomarker signature integration into clinical decision support systems. Rigorous validation and standardization efforts are also necessary to ensure these biomarkers are clinically useful. Large-scale collaborative research will be vital to driving progress in this field and implementing these biomarkers in clinical practice. This comprehensive review highlights the potential of biomarkers to transform acute and chronic pain management, offering hope for improved diagnosis, treatment personalization, and patient outcomes.
疼痛影响着全球数百万人,在诊断和治疗方面带来了重大挑战。尽管在理解疼痛机制方面取得了进展,但仍迫切需要经过验证的生物标志物来加强诊断、预后评估和个性化治疗。这篇综述综合了在识别和验证急性和慢性疼痛生物标志物方面的最新进展,包括影像学、分子、感觉和神经生理学方法。我们强调了综合多模态策略的出现,这些策略整合了社会心理因素,以提高生物标志物在慢性疼痛管理中的准确性和适用性。像磁共振成像(MRI)和正电子发射断层扫描这样的神经成像技术能够洞察与疼痛相关的结构和功能异常,而像脑电图和脑磁图这样的电生理方法则评估疼痛神经轴中的功能失调处理。分子生物标志物,包括细胞因子、蛋白质组学和代谢产物,具有诊断和预后潜力,不过还需要广泛验证。将这些生物标志物与社会心理因素整合到临床实践中,可以通过实现个性化治疗策略、改善患者预后并可能降低医疗成本,彻底改变疼痛管理。未来的方向包括开发复合生物标志物特征、人工智能的进展以及将生物标志物特征整合到临床决策支持系统中。严格的验证和标准化工作对于确保这些生物标志物在临床上有用也很有必要。大规模的合作研究对于推动该领域的进展以及在临床实践中应用这些生物标志物至关重要。这篇全面的综述突出了生物标志物在改变急性和慢性疼痛管理方面的潜力,为改善诊断、治疗个性化和患者预后带来了希望。